Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Clinical trial NCT02112526 · COMPLETED
Trial details
- NCT number
- NCT02112526
- Sponsor
- Acerta Pharma BV
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-08-07
- Primary completion
- 2020-06-30
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.